Covered recipient · General Payments record
CHARLES HARPER
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$1,808.80
124 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,808.80 | 124 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $353.61 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $215.06 | 14 |
| Novo Nordisk Inc | $164.68 | 15 |
| Lilly USA, LLC | $150.62 | 14 |
| Mannkind Corporation | $138.20 | 8 |
| Janssen Pharmaceuticals, Inc | $118.35 | 10 |
| IRONWOOD PHARMACEUTICALS, INC | $83.27 | 5 |
| PFIZER INC. | $77.61 | 7 |
| Avanir Pharmaceuticals, Inc. | $65.33 | 4 |
| Amarin Pharma Inc. | $63.74 | 4 |
| SANOFI-AVENTIS U.S. LLC | $62.91 | 4 |
| Amgen Inc. | $58.55 | 4 |
| Merck Sharp & Dohme Corporation | $45.31 | 3 |
| GlaxoSmithKline, LLC. | $37.59 | 3 |
| Daiichi Sankyo Inc. | $28.73 | 2 |
| Astellas Pharma US Inc | $26.87 | 2 |
| Arbor Pharmaceuticals, Inc. | $24.97 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.64 | 1 |
| AbbVie Inc. | $16.71 | 1 |
| Biohaven Pharmaceuticals, Inc. | $15.36 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.64 | 1 |
| Esperion Therapeutics, Inc. | $13.40 | 1 |
| Novartis Pharmaceuticals Corporation | $12.65 | 1 |
Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CHARLES HARPER
NPI 1063620961 · CMS profile ID 229937
Allopathic & Osteopathic Physicians / Internal Medicine
NORFOLK, NE
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1063620961?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CHARLES HARPER, NPI 1063620961, CMS profile ID 229937. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063620961?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). CHARLES HARPER, NPI 1063620961, CMS profile ID 229937. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063620961?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- CHARLES HARPER, NPI 1063620961, CMS profile ID 229937, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1063620961?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
124 matching records · $1,808.80 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 124.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | $15.69 | 08/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744870489 | CMS |
| Lilly USA, LLC | $12.96 | 08/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728361463 | CMS |
| PFIZER INC. | $7.63 | 07/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743744839 | CMS |
| Arbor Pharmaceuticals, Inc. | $13.50 | 07/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735728617 | CMS |
| Amarin Pharma Inc. | $21.19 | 07/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739839590 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.13 | 07/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720774317 | CMS |
| PFIZER INC. | $11.34 | 07/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743743733 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.64 | 07/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737538575 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.63 | 07/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736171147 | CMS |
| Novo Nordisk Inc | $10.53 | 07/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 745024923 | CMS |
| Avanir Pharmaceuticals, Inc. | $14.35 | 07/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722211523 | CMS |
| Mannkind Corporation | $13.28 | 07/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752671573 | CMS |
| Novo Nordisk Inc | $12.06 | 07/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744789105 | CMS |
| Lilly USA, LLC | $12.22 | 07/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728361461 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.61 | 07/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735998209 | CMS |
| Novo Nordisk Inc | $15.24 | 06/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744762261 | CMS |
| Janssen Pharmaceuticals, Inc | $11.21 | 06/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719077141 | CMS |
| Astellas Pharma US Inc | $12.54 | 06/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 718331157 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.20 | 06/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720774323 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $13.82 | 06/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749828745 | CMS |
| Novo Nordisk Inc | $4.85 | 06/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744775283 | CMS |
| Lilly USA, LLC | $12.75 | 06/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728364907 | CMS |
| Lilly USA, LLC | $2.53 | 06/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728368367 | CMS |
| Merck Sharp & Dohme Corporation | $18.19 | 06/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747677635 | CMS |
| Mannkind Corporation | $17.08 | 06/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752671571 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.29 | 06/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736239193 | CMS |
| SANOFI-AVENTIS U.S. LLC | $13.23 | 06/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744258787 | CMS |
| Novo Nordisk Inc | $11.43 | 06/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744696599 | CMS |
| Novo Nordisk Inc | $13.27 | 06/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744698423 | CMS |
| Avanir Pharmaceuticals, Inc. | $14.45 | 06/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722211457 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.76 | 05/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720774329 | CMS |
| Janssen Pharmaceuticals, Inc | $14.12 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719077139 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.86 | 05/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736315505 | CMS |
| Astellas Pharma US Inc | $14.33 | 05/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 718331155 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.17 | 05/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720774333 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $17.46 | 05/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749820801 | CMS |
| GlaxoSmithKline, LLC. | $11.45 | 05/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738569311 | CMS |
| PFIZER INC. | $9.45 | 05/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743725711 | CMS |
| Janssen Pharmaceuticals, Inc | $14.39 | 05/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719077135 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $21.83 | 04/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749818883 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.76 | 04/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720774337 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.28 | 04/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735854127 | CMS |
| Janssen Pharmaceuticals, Inc | $9.11 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719077137 | CMS |
| Novo Nordisk Inc | $10.96 | 04/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744666973 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.76 | 04/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720774341 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.18 | 04/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735895633 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.63 | 04/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736295691 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.32 | 03/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735982031 | CMS |
| Amarin Pharma Inc. | $11.73 | 03/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739827273 | CMS |
| Novo Nordisk Inc | $9.58 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744639661 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,597,319.56 | 478 |
| PY2024 | Principal investigator | $5,628,700.46 | 398 |
| PY2023 | Principal investigator | $5,967,726.31 | 1,617 |
| PY2022 | Principal investigator | $10,695,952.45 | 1,759 |
| PY2021 | Principal investigator | $2,712,728.19 | 172 |
| PY2020 | Principal investigator | $1,871,094.84 | 66 |
| PY2019 | Principal investigator | $595,554.83 | 81 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
478 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $18,800.00 | 12/31/2025 | Non-covered Recipient Entity Velocity Clinical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228805184 |
| Principal investigator 1 | PFIZER INC. | $2,251.88 | 12/31/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228816924 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,160.00 | 12/26/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226089964 |
| Principal investigator 1 | ModernaTX, Inc. | $1,940.86 | 12/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950004 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,500.00 | 12/22/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226115291 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,811.00 | 12/22/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226115299 |
| Principal investigator 1 | ModernaTX, Inc. | $3,324.24 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252949998 |
| Principal investigator 1 | ModernaTX, Inc. | $199.80 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950028 |
| Principal investigator 1 | ModernaTX, Inc. | $29.50 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950046 |
| Principal investigator 1 | ModernaTX, Inc. | $68.85 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950052 |
| Principal investigator 1 | ModernaTX, Inc. | $148.50 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950084 |
| Principal investigator 1 | ModernaTX, Inc. | $6,959.70 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994410 |
| Principal investigator 1 | ModernaTX, Inc. | $16,876.75 | 12/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994414 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271802 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271804 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271806 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271808 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271810 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271812 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271814 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271816 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271818 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271820 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271822 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271824 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271826 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271828 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271830 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271832 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185271834 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273020 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273028 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273030 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273032 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273034 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185273044 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279629 |
| Principal investigator 1 | Seqirus USA Inc | $47.60 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185279631 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280237 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280239 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280241 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280243 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280245 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280729 |
| Principal investigator 1 | Seqirus USA Inc | $819.00 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185280731 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282663 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282665 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282667 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282669 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282671 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282673 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282675 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282677 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282679 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282681 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282683 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282685 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282687 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282689 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282691 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282693 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282695 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282697 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282699 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282701 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282703 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282705 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282707 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282709 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282711 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282713 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282715 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282717 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282719 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282721 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282723 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282993 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282995 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282997 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185282999 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283001 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283003 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283005 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283007 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283009 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283011 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283013 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283015 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283017 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283019 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283021 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283023 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283025 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283027 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283029 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283031 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283033 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283035 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283037 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283039 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283041 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283043 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283045 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283047 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283049 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283051 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283053 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283055 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283057 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283059 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283061 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283063 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283065 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/19/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185283067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $122.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175240871 |
| Principal investigator 1 | Seqirus USA Inc | $406.00 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274106 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274240 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274242 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274244 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274246 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274248 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274250 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274252 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274254 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274256 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274258 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274260 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274262 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274264 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274266 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274268 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274270 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274272 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274274 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274294 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274492 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274496 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274498 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274500 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274502 |
| Principal investigator 1 | Seqirus USA Inc | $1,061.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274504 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274810 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274812 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274814 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274816 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274818 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274820 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274822 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274824 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274826 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274828 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274830 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274832 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274834 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274836 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274838 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274840 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274842 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274844 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274846 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274848 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274850 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274852 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274854 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274856 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274858 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274860 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274862 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274864 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274866 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274868 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274870 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274872 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274874 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274876 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274878 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274880 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274882 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274884 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274886 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274888 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274890 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274892 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274894 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274896 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274898 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274900 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274902 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274904 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274906 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274908 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274910 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274912 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274914 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274916 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274918 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274920 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274922 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185274924 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275098 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275100 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275102 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275104 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275106 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275108 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275110 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275112 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275114 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275116 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275118 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275120 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275122 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275124 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275126 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275128 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275131 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275134 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275136 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275138 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275140 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275142 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275144 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275146 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275148 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275150 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275152 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275154 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275156 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275158 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275160 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275162 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275164 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275166 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275168 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275170 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275172 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275174 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275176 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275178 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275180 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275182 |
| Principal investigator 1 | Seqirus USA Inc | $3,518.20 | 12/18/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185275184 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 12/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) | No dispute reported | 06/30/2026 | 1252946504 |
| Principal investigator 1 | PFIZER INC. | $585.00 | 12/16/2025 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228805190 |
| Principal investigator 1 | ModernaTX, Inc. | $800.00 | 12/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994342 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809406 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809413 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809418 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809454 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809460 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809465 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809494 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809500 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809512 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809516 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809521 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809580 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228809666 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228810090 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228810098 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228810102 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228810142 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228810439 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228810444 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/08/2025 | Non-covered Recipient Entity Velocity Clinical Research Norfolk | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228810450 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 12/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252950068 |
| Principal investigator 1 | ModernaTX, Inc. | $4,676.00 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950002 |
| Principal investigator 1 | ModernaTX, Inc. | $3,426.84 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950006 |
| Principal investigator 1 | ModernaTX, Inc. | $29.50 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950030 |
| Principal investigator 1 | ModernaTX, Inc. | $324.50 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950048 |
| Principal investigator 1 | ModernaTX, Inc. | $278.35 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994320 |
| Principal investigator 1 | ModernaTX, Inc. | $36,731.75 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994380 |
| Principal investigator 1 | ModernaTX, Inc. | $7,503.10 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994416 |
| Principal investigator 1 | ModernaTX, Inc. | $1,444.00 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010368 |
| Principal investigator 1 | ModernaTX, Inc. | $425.00 | 11/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010378 |
| Principal investigator 1 | ModernaTX, Inc. | $105.00 | 11/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994300 |
| Principal investigator 1 | ModernaTX, Inc. | $30,000.00 | 11/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) | No dispute reported | 06/30/2026 | 1252946502 |
| Principal investigator 1 | ModernaTX, Inc. | $1,600.00 | 11/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252949996 |
| Principal investigator 1 | ModernaTX, Inc. | $800.00 | 11/20/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950032 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $294,184.80 | 11/14/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115310 |
| Principal investigator 1 | Seqirus USA Inc | $3,419.20 | 11/12/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809772 |
| Principal investigator 1 | Seqirus USA Inc | $939.60 | 11/12/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809777 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,062.90 | 11/05/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226090349 |
| Principal investigator 1 | Seqirus USA Inc | $939.60 | 10/31/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809951 |
| Principal investigator 1 | Seqirus USA Inc | $3,419.20 | 10/31/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age | No dispute reported | 06/30/2026 | 1250809954 |
| Principal investigator 1 | ModernaTX, Inc. | $23,088.80 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252949990 |
| Principal investigator 1 | ModernaTX, Inc. | $28,272.00 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252950038 |
| Principal investigator 1 | ModernaTX, Inc. | $1,846.80 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950050 |
| Principal investigator 1 | ModernaTX, Inc. | $29.50 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950076 |
| Principal investigator 1 | ModernaTX, Inc. | $24,818.75 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994294 |
| Principal investigator 1 | ModernaTX, Inc. | $17,794.65 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994302 |
| Principal investigator 1 | ModernaTX, Inc. | $717.92 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994304 |
| Principal investigator 1 | ModernaTX, Inc. | $7,997.68 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994314 |
| Principal investigator 1 | ModernaTX, Inc. | $6,925.50 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994344 |
| Principal investigator 1 | ModernaTX, Inc. | $29,176.94 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994348 |
| Principal investigator 1 | ModernaTX, Inc. | $1,670.10 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994364 |
| Principal investigator 1 | ModernaTX, Inc. | $26,291.25 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994392 |
| Principal investigator 1 | ModernaTX, Inc. | $7,503.10 | 10/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994420 |
| Principal investigator 1 | PFIZER INC. | $3,675.00 | 10/25/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228825189 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $43,967.70 | 10/23/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226090318 |
| Principal investigator 1 | Seqirus USA Inc | $360.34 | 10/13/2025 | Non-covered Recipient Entity Meridian Clinical Research | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297728 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $24,754.80 | 10/10/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115080 |
| Principal investigator 1 | ModernaTX, Inc. | $16,963.20 | 09/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252949976 |
| Principal investigator 1 | ModernaTX, Inc. | $29.50 | 09/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950034 |
| Principal investigator 1 | ModernaTX, Inc. | $13,406.40 | 09/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252950040 |
| Principal investigator 1 | ModernaTX, Inc. | $4,453.60 | 09/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994290 |
| Principal investigator 1 | ModernaTX, Inc. | $7,419.50 | 09/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,000.00 | 09/24/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175239087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 09/24/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175239497 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,260.00 | 09/24/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175239756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,255.00 | 09/24/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175240116 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,250.00 | 09/24/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175240208 |
| Principal investigator 1 | ModernaTX, Inc. | $902.11 | 09/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252949992 |
| Principal investigator 1 | ModernaTX, Inc. | $11,477.79 | 09/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252949994 |
| Principal investigator 1 | ModernaTX, Inc. | $6,758.18 | 09/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252950044 |
| Principal investigator 1 | ModernaTX, Inc. | $448.97 | 09/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252950066 |
| Principal investigator 1 | ModernaTX, Inc. | $33.75 | 09/23/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH-NORFOLK | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950026 |
| Principal investigator 1 | Janssen Research & Development, LLC | $268.80 | 09/22/2025 | Non-covered Recipient Entity Meridian Clinic Rsrch | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244116 |
| Principal investigator 1 | Janssen Research & Development, LLC | $570.00 | 09/19/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175239781 |
| Principal investigator 1 | Seqirus USA Inc | $946.80 | 09/18/2025 | Non-covered Recipient Entity Meridian Clinical Research | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297752 |
| Principal investigator 1 | Seqirus USA Inc | $110.98 | 09/18/2025 | Non-covered Recipient Entity Meridian Clinical Research | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297756 |
| Principal investigator 1 | Seqirus USA Inc | $111.30 | 09/18/2025 | Non-covered Recipient Entity Meridian Clinical Research | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185297760 |
| Principal investigator 1 | ModernaTX, Inc. | $1,350.00 | 09/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950086 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 09/15/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994266 |
| Principal investigator 1 | ModernaTX, Inc. | $800.00 | 09/08/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,600.00 | 09/01/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175239579 |
| Principal investigator 1 | ModernaTX, Inc. | $4,676.00 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950000 |
| Principal investigator 1 | ModernaTX, Inc. | $383.50 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950008 |
| Principal investigator 1 | ModernaTX, Inc. | $372.40 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252950024 |
| Principal investigator 1 | ModernaTX, Inc. | $4,851.90 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950074 |
| Principal investigator 1 | ModernaTX, Inc. | $6,648.48 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950078 |
| Principal investigator 1 | ModernaTX, Inc. | $341.55 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950082 |
| Principal investigator 1 | ModernaTX, Inc. | $5,819.98 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950088 |
| Principal investigator 1 | ModernaTX, Inc. | $6,853.68 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950090 |
| Principal investigator 1 | ModernaTX, Inc. | $35.00 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994270 |
| Principal investigator 1 | ModernaTX, Inc. | $992.75 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994292 |
| Principal investigator 1 | ModernaTX, Inc. | $7,879.30 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994336 |
| Principal investigator 1 | ModernaTX, Inc. | $6,123.70 | 08/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994362 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,119.00 | 08/20/2025 | Non-covered Recipient Entity Meridian Clinical Research | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225408584 |
| Principal investigator 1 | ModernaTX, Inc. | $75.00 | 08/20/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994262 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 08/20/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994310 |
| Principal investigator 1 | ModernaTX, Inc. | $70.00 | 08/20/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994350 |
| Principal investigator 1 | ModernaTX, Inc. | $105.00 | 08/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994308 |
| Principal investigator 1 | ModernaTX, Inc. | $1,797.40 | 08/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994318 |
| Principal investigator 1 | ModernaTX, Inc. | $8,628.85 | 08/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994324 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 08/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994398 |
| Principal investigator 1 | PFIZER INC. | $5,800.00 | 08/16/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1228843292 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 08/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950054 |
| Principal investigator 1 | Seqirus USA Inc | $14,500.00 | 08/01/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276902 |
| Principal investigator 1 | Seqirus USA Inc | $27,126.40 | 08/01/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276920 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,844.00 | 07/31/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175239586 |
| Principal investigator 1 | Janssen Research & Development, LLC | $476.00 | 07/31/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175240469 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 07/30/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age | No dispute reported | 06/30/2026 | 1185276970 |
| Principal investigator 1 | ModernaTX, Inc. | $461.52 | 07/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994274 |
| Principal investigator 1 | ModernaTX, Inc. | $21,993.62 | 07/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994276 |
| Principal investigator 1 | ModernaTX, Inc. | $26,932.56 | 07/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994316 |
| Principal investigator 1 | ModernaTX, Inc. | $7,361.55 | 07/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994346 |
| Principal investigator 1 | ModernaTX, Inc. | $12,720.00 | 07/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010366 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,700.00 | 07/01/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175239276 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 06/30/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994268 |
| Principal investigator 1 | ModernaTX, Inc. | $5,475.80 | 06/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994296 |
| Principal investigator 1 | ModernaTX, Inc. | $8,934.75 | 06/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994298 |
| Principal investigator 1 | ModernaTX, Inc. | $3,618.55 | 06/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994322 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,394.00 | 06/26/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175240213 |
| Principal investigator 1 | PFIZER INC. | $2,670.00 | 06/26/2025 | Non-covered Recipient Entity Meridian Clinical Research LLC | A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228852351 |
| Principal investigator 1 | ModernaTX, Inc. | $6,798.20 | 06/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252950070 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994280 |
| Principal investigator 1 | ModernaTX, Inc. | $245.00 | 06/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994340 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 06/25/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994404 |
| Principal investigator 1 | Seqirus USA Inc | $89,869.05 | 06/25/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age | No dispute reported | 06/30/2026 | 1185277089 |
| Principal investigator 1 | ModernaTX, Inc. | $7,670.30 | 06/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994286 |
| Principal investigator 1 | ModernaTX, Inc. | $16,876.75 | 06/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994412 |
| Principal investigator 1 | ModernaTX, Inc. | $3,061.85 | 06/18/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994426 |
| Principal investigator 1 | ModernaTX, Inc. | $48,640.00 | 06/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010376 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $198,416.40 | 06/12/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115285 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $109,571.00 | 06/12/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115295 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,000.00 | 06/11/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure | No dispute reported | 06/30/2026 | 1185541340 |
| Principal investigator 1 | Seqirus USA Inc | $187.50 | 06/11/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age | No dispute reported | 06/30/2026 | 1185277087 |
| Principal investigator 1 | Seqirus USA Inc | $1,895.00 | 06/11/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age | No dispute reported | 06/30/2026 | 1185277091 |
| Principal investigator 1 | Seqirus USA Inc | $580.00 | 06/11/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age | No dispute reported | 06/30/2026 | 1185277093 |
| Principal investigator 1 | Seqirus USA Inc | $1,500.00 | 06/11/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age | No dispute reported | 06/30/2026 | 1185277095 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 06/09/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115205 |
| Principal investigator 1 | ModernaTX, Inc. | $825.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010364 |
| Principal investigator 1 | ModernaTX, Inc. | $25,375.00 | 06/05/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010370 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $14,263.90 | 06/02/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226115110 |
| Principal investigator 1 | ModernaTX, Inc. | $11,600.00 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252949978 |
| Principal investigator 1 | ModernaTX, Inc. | $129,618.00 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252949980 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252949982 |
| Principal investigator 1 | ModernaTX, Inc. | $47,120.00 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252949986 |
| Principal investigator 1 | ModernaTX, Inc. | $9,000.00 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252949988 |
| Principal investigator 1 | ModernaTX, Inc. | $2,802.00 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252950042 |
| Principal investigator 1 | ModernaTX, Inc. | $6,958.75 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994288 |
| Principal investigator 1 | ModernaTX, Inc. | $25,811.50 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994358 |
| Principal investigator 1 | ModernaTX, Inc. | $7,210.50 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994370 |
| Principal investigator 1 | ModernaTX, Inc. | $686.85 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994384 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,000.00 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226090379 |
| Principal investigator 1 | ModernaTX, Inc. | $1,002.00 | 05/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010358 |
| Principal investigator 1 | ModernaTX, Inc. | $188,480.00 | 05/22/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010360 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,050.00 | 05/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure | No dispute reported | 06/30/2026 | 1185541342 |
| Principal investigator 1 | ModernaTX, Inc. | $650.00 | 05/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252950018 |
| Principal investigator 1 | ModernaTX, Inc. | $8,750.00 | 05/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252950092 |
| Principal investigator 1 | ModernaTX, Inc. | $202.50 | 05/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994278 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 05/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $368.00 | 05/20/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175241115 |
| Principal investigator 1 | ModernaTX, Inc. | $550.00 | 05/07/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252950014 |
| Principal investigator 1 | ModernaTX, Inc. | $573.16 | 05/07/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252950016 |
| Principal investigator 1 | ModernaTX, Inc. | $1,200.00 | 05/07/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252950020 |
| Principal investigator 1 | ModernaTX, Inc. | $29,155.32 | 05/07/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1252950072 |
| Principal investigator 1 | ModernaTX, Inc. | $1,910.00 | 05/02/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252950036 |
| Principal investigator 1 | ModernaTX, Inc. | $14,723.10 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994354 |
| Principal investigator 1 | ModernaTX, Inc. | $35,739.00 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994366 |
| Principal investigator 1 | ModernaTX, Inc. | $16,701.00 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994418 |
| Principal investigator 1 | ModernaTX, Inc. | $7,168.70 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994422 |
| Principal investigator 1 | ModernaTX, Inc. | $2,004.00 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010372 |
| Principal investigator 1 | ModernaTX, Inc. | $36.50 | 04/23/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH-NORFOLK | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994356 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $69,390.30 | 04/22/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226090747 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,090.00 | 04/17/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175241050 |
| Principal investigator 1 | ModernaTX, Inc. | $7,361.55 | 04/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994312 |
| Principal investigator 1 | ModernaTX, Inc. | $20,276.58 | 04/16/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994396 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 04/07/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994282 |
| Principal investigator 1 | ModernaTX, Inc. | $435.00 | 04/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH-NORFOLK | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950056 |
| Principal investigator 1 | ModernaTX, Inc. | $49.89 | 04/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH-NORFOLK | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994264 |
| Principal investigator 1 | ModernaTX, Inc. | $8.50 | 03/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH-NORFOLK | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252950080 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $77,170.81 | 03/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH NORFOLK | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214125030 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,857.60 | 03/24/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175240380 |
| Principal investigator 1 | ModernaTX, Inc. | $24,494.80 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994328 |
| Principal investigator 1 | ModernaTX, Inc. | $992.75 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994334 |
| Principal investigator 1 | ModernaTX, Inc. | $6,604.40 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994374 |
| Principal investigator 1 | ModernaTX, Inc. | $3,040.00 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010354 |
| Principal investigator 1 | ModernaTX, Inc. | $1,336.00 | 03/24/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010362 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 03/21/2025 | Non-covered Recipient Entity MERIDIAN CLINICAL RESEARCH LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252950012 |
| Principal investigator 1 | ModernaTX, Inc. | $1,600.43 | 03/19/2025 | Non-covered Recipient Entity MERIDIAN CLINICAL RESEARCH LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252950058 |
| Principal investigator 1 | ModernaTX, Inc. | $17,800.00 | 03/19/2025 | Non-covered Recipient Entity MERIDIAN CLINICAL RESEARCH LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252950062 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 03/19/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226091373 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $136,429.30 | 03/19/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226091644 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $800.00 | 03/19/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226114843 |
| Principal investigator 1 | ModernaTX, Inc. | $2,800.00 | 03/13/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994306 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 03/13/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994388 |
| Principal investigator 1 | ModernaTX, Inc. | $145.60 | 03/10/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH-NORFOLK | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252950022 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $130,965.10 | 03/03/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226090983 |
| Principal investigator 1 | ModernaTX, Inc. | $104.00 | 02/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH-SPRINGDALE | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252949984 |
| Principal investigator 1 | ModernaTX, Inc. | $8,046.50 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994332 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994352 |
| Principal investigator 1 | ModernaTX, Inc. | $686.85 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994360 |
| Principal investigator 1 | ModernaTX, Inc. | $2,866.15 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994368 |
| Principal investigator 1 | ModernaTX, Inc. | $250.80 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994372 |
| Principal investigator 1 | ModernaTX, Inc. | $23,659.75 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994378 |
| Principal investigator 1 | ModernaTX, Inc. | $11,913.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994424 |
| Principal investigator 1 | ModernaTX, Inc. | $3,006.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010382 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,416.00 | 02/19/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175240271 |
| Principal investigator 1 | ModernaTX, Inc. | $83.20 | 02/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH-SPRINGDALE | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age | No dispute reported | 06/30/2026 | 1252950064 |
| Principal investigator 1 | ModernaTX, Inc. | $5,732.30 | 02/19/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994338 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 02/13/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226092343 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,000.00 | 02/06/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226115356 |
| Principal investigator 1 | ModernaTX, Inc. | $2,400.00 | 02/03/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994272 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,890.00 | 02/03/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226092358 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,550.00 | 02/03/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226092376 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 02/03/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226092395 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $26,863.20 | 02/03/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226092414 |
| Principal investigator 1 | ModernaTX, Inc. | $418.50 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994394 |
| Principal investigator 1 | ModernaTX, Inc. | $14,812.80 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994400 |
| Principal investigator 1 | ModernaTX, Inc. | $4,251.52 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994402 |
| Principal investigator 1 | ModernaTX, Inc. | $57,231.69 | 01/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | No dispute reported | 06/30/2026 | 1252994408 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $44,815.40 | 01/29/2025 | Non-covered Recipient Entity Velocity Clinical Research,inc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226092348 |
| Principal investigator 1 | ModernaTX, Inc. | $13,639.15 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994284 |
| Principal investigator 1 | ModernaTX, Inc. | $1,630.20 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994326 |
| Principal investigator 1 | ModernaTX, Inc. | $11,464.60 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994330 |
| Principal investigator 1 | ModernaTX, Inc. | $4,305.40 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994376 |
| Principal investigator 1 | ModernaTX, Inc. | $12,905.75 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252994382 |
| Principal investigator 1 | ModernaTX, Inc. | $1,520.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010356 |
| Principal investigator 1 | ModernaTX, Inc. | $12,540.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010374 |
| Principal investigator 1 | ModernaTX, Inc. | $4,008.00 | 01/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010380 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,674.00 | 01/21/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175239649 |
| Principal investigator 1 | Janssen Research & Development, LLC | $676.00 | 01/17/2025 | Non-covered Recipient Entity Velocity Clnc Research, Inc. | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175240885 |
| Principal investigator 1 | Seqirus USA Inc | $471.60 | 01/17/2025 | Non-covered Recipient Entity Velocity Clinical Research, Inc. | A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age | No dispute reported | 06/30/2026 | 1185277375 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 01/10/2025 | Non-covered Recipient Entity MERIDIAN CLINICAL RESEARCH LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252950010 |
| Principal investigator 1 | ModernaTX, Inc. | $1,200.00 | 01/10/2025 | Non-covered Recipient Entity MERIDIAN CLINICAL RESEARCH LLC | A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive | No dispute reported | 06/30/2026 | 1252950060 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $137,866.59 | 01/01/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH NORFOLK | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214125322 |